Discovery of KT-474-a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases

被引：14

作者：

Zheng, Xiaozhang ^{[1
]}

Ji, Nan ^{[1
]}

Campbell, Veronica ^{[1
]}

Slavin, Anthony ^{[1
]}

Zhu, Xiao ^{[1
]}

Chen, Dapeng ^{[1
]}

Rong, Haojing ^{[1
]}

Enerson, Brad ^{[1
]}

Mayo, Michele ^{[1
]}

Sharma, Kirti ^{[1
]}

Browne, Chris M. ^{[1
]}

Klaus, Christine R. ^{[1
]}

Li, Haoran ^{[1
]}

Massa, Ginny ^{[1
]}

McDonald, Alice A. ^{[1
]}

Shi, Yatao ^{[1
]}

Sintchak, Mike ^{[1
]}

Skouras, Stephanie ^{[1
]}

Walther, Dirk M. ^{[1
]}

Yuan, Karen ^{[1
]}

Zhang, Yi ^{[1
]}

Kelleher, Joe ^{[1
]}

Liu, Guang ^{[1
]}

Luo, Xinbo ^{[1
]}

Mainolfi, Nello ^{[1
]}

Weiss, Matthew M. ^{[1
]}

机构：

[1] Kymera Therapeut, Watertown, MA 02472 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 20期

关键词：

CHIRAL INVERSION; KINASE; 4; DEGRADATION; INHIBITORS;

D O I：

10.1021/acs.jmedchem.4c01305

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Interleukin-1 receptor associated kinase 4 (IRAK4) is an essential mediator of the IL-1R and TLR signaling pathways, both of which have been implicated in multiple autoimmune conditions. Hence, blocking the activity of IRAK4 represents an attractive approach for the treatment of autoimmune diseases. The activity of this serine/threonine kinase is dependent on its kinase and scaffolding activities; thus, degradation represents a potentially superior approach to inhibition. Herein, we detail the exploration of structure-activity relationships that ultimately led to the identification of KT-474, a potent, selective, and orally bioavailable heterobifunctional IRAK4 degrader. This represents the first heterobifunctional degrader evaluated in a nononcology indication and dosed to healthy human volunteers. This molecule successfully completed phase I studies in healthy adult volunteers and patients with atopic dermatitis or hidradenitis suppurativa. Phase II clinical trials in both of these indications have been initiated.

引用

页码：18022 / 18037

页数：16

共 37 条

[1] IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial [J].

Ackerman, Lindsay ;

Acloque, Gerard ;

Bacchelli, Sandro ;

Schwartz, Howard ;

Feinstein, Brian J. ;

La Stella, Phillip ;

Alavi, Afsaneh ;

Gollerkeri, Ashwin ;

Davis, Jeffrey ;

Campbell, Veronica ;

Mcdonald, Alice ;

Agarwal, Sagar ;

Karnik, Rahul ;

Shi, Kelvin ;

Mishkin, Aimee ;

Culbertson, Jennifer ;

Klaus, Christine ;

Enerson, Bradley ;

Massa, Virginia ;

Kuhn, Eric ;

Sharma, Kirti ;

Keaney, Erin ;

Barnes, Randy ;

Chen, Dapeng ;

Zheng, Xiaozhang ;

Rong, Haojing ;

Sabesan, Vijay ;

Ho, Chris ;

Mainolfi, Nello ;

Slavin, Anthony ;

Gollob, Jared A. .

NATURE MEDICINE, 2023, 29 (12) :3127-3136

[2] Trial of Spesolimab for Generalized Pustular Psoriasis [J].

Bachelez, H. ;

Choon, S-E ;

Marrakchi, S. ;

Burden, A. D. ;

Tsai, T-F ;

Morita, A. ;

Navarini, A. A. ;

Zheng, M. ;

Xu, J. ;

Turki, H. ;

Anadkat, M. J. ;

Rajeswari, S. ;

Hua, H. ;

Vulcu, S. D. ;

Hall, D. ;

Tetzlaff, K. ;

Thoma, C. ;

Lebwohl, M. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (26) :2431-2440

[3] Understanding early TLR signaling through the Myddosome [J].

Balka, Katherine R. ;

De Nardo, Dominic .

JOURNAL OF LEUKOCYTE BIOLOGY, 2019, 105 (02) :339-351

[4] Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4 [J].

Belair, David G. ;

Lu, Gang ;

Waller, Laura E. ;

Gustin, Jason A. ;

Collins, Nathaniel D. ;

Kolaja, Kyle L. .

SCIENTIFIC REPORTS, 2020, 10 (01)

[5] Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs [J].

Chamberlain, Philip P. ;

Lopez-Girona, Antonia ;

Miller, Karen ;

Carmel, Gilles ;

Pagarigan, Barbra ;

Chie-Leon, Barbara ;

Rychak, Emily ;

Corral, Laura G. ;

Ren, Yan J. ;

Wang, Maria ;

Riley, Mariko ;

Delker, Silvia L. ;

Ito, Takumi ;

Ando, Hideki ;

Mori, Tomoyuki ;

Hirano, Yoshinori ;

Handa, Hiroshi ;

Hakoshima, Toshio ;

Daniel, Thomas O. ;

Cathers, Brian E. .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2014, 21 (09) :803-809

[6] Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders [J].

Chaudhary, Divya ;

Robinson, Shaughnessy ;

Romero, Donna L. .

JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (01) :96-110

[7] Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs [J].

Chen, Yun ;

Ning, Yi ;

Bai, Gang ;

Tong, Linjiang ;

Zhang, Tao ;

Zhou, Jinpei ;

Zhang, Huibin ;

Xie, Hua ;

Ding, Jian ;

Duan, Wenhu .

ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (01) :82-87

[8] Interleukin 1/Toll-like Receptor-induced Autophosphorylation Activates Interleukin 1 Receptor-associated Kinase 4 and Controls Cytokine Induction in a Cell Type-specific Manner [J].

Cushing, Leah ;

Stochaj, Wayne ;

Siegel, Marshall ;

Czerwinski, Robert ;

Dower, Ken ;

Wright, Quentin ;

Hirschfield, Margaret ;

Casanova, Jean-Laurent ;

Picard, Capucine ;

Puel, Anne ;

Lin, Lih-Ling ;

Rao, Vikram R. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (15) :10865-10875

[9]

Danto S., 2019, EFFICACYAND SAFETY S

[10] Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling [J].

De Nardo, Dominic ;

Balka, Katherine R. ;

Gloria, Yamel Cardona ;

Rao, Vikram R. ;

Latz, Eicke ;

Masters, Seth L. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (39) :15195-15207

← 1 2 3 4 →